These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33861183)

  • 1. Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.
    Kumar P; Shukla RS; Patel A; Pullagurla SR; Bird C; Ogun O; Kumru OS; Hamidi A; Hoeksema F; Yallop C; Bines JE; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2021 Jul; 17(7):2298-2310. PubMed ID: 33861183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Formulation Variables on the Stability of a Live, Rotavirus (RV3-BB) Vaccine Candidate using in vitro Gastric Digestion Models to Mimic Oral Delivery.
    Kumar P; Pullagurla SR; Patel A; Shukla RS; Bird C; Kumru OS; Hamidi A; Hoeksema F; Yallop C; Bines JE; Joshi SB; Volkin DB
    J Pharm Sci; 2021 Feb; 110(2):760-770. PubMed ID: 33035539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the long-term 2-8 °C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data.
    Pullagurla SR; Kumar P; Ogun O; Kumru OS; Hamidi A; Hoeksema F; Yallop C; Bines JE; Volkin DB; Joshi SB
    Biologicals; 2022 Jan; 75():21-28. PubMed ID: 34924260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.
    Cowley D; Boniface K; Bogdanovic-Sakran N; Kirkwood CD; Bines JE
    Hum Vaccin Immunother; 2017 Aug; 13(8):1908-1915. PubMed ID: 28481726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.
    Danchin M; Kirkwood CD; Lee KJ; Bishop RF; Watts E; Justice FA; Clifford V; Cowley D; Buttery JP; Bines JE
    Vaccine; 2013 May; 31(23):2610-6. PubMed ID: 23597719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
    Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD;
    Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand.
    Chen MY; Kirkwood CD; Bines J; Cowley D; Pavlic D; Lee KJ; Orsini F; Watts E; Barnes G; Danchin M
    Hum Vaccin Immunother; 2017 May; 13(5):1126-1135. PubMed ID: 28059609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.
    Cowley D; Pavlic D; Bogdanovic-Sakran N; Boniface K; Kirkwood CD; Bines JE
    Hum Vaccin Immunother; 2018; 14(8):2082-2087. PubMed ID: 29688121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.
    Witte D; Handley A; Jere KC; Bogandovic-Sakran N; Mpakiza A; Turner A; Pavlic D; Boniface K; Mandolo J; Ong DS; Bonnici R; Justice F; Bar-Zeev N; Iturriza-Gomara M; Ackland J; Donato CM; Cowley D; Barnes G; Cunliffe NA; Bines JE
    Lancet Infect Dis; 2022 May; 22(5):668-678. PubMed ID: 35065683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB).
    Cowley D; Sari RM; Handley A; Watts E; Bachtiar NS; At Thobari J; Satria CD; Bogdanovic-Sakran N; Nirwati H; Orsini F; Lee KJ; Kirkwood CD; Soenarto Y; Bines JE
    Vaccine; 2019 Nov; 37(49):7233-7239. PubMed ID: 31607604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine.
    Hamidi A; Hoeksema F; Velthof P; Lemckert A; Gillissen G; Luitjens A; Bines JE; Pullagurla SR; Kumar P; Volkin DB; Joshi SB; Havenga M; Bakker WAM; Yallop C
    Vaccine; 2021 Apr; 39(15):2048-2059. PubMed ID: 33744044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule.
    Geard N; Bradhurst R; Tellioglu N; Oktaria V; McVernon J; Handley A; Bines JE
    Hum Vaccin Immunother; 2022 Nov; 18(6):2139097. PubMed ID: 36409459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.
    At Thobari J; Damayanti W; Haposan JH; Nirwati H; Iskandar K; Samad ; Fahmi J; Sari RM; Bachtiar NS; Watts E; Bines JE; Soenarto Y
    Vaccine; 2021 Jul; 39(33):4651-4658. PubMed ID: 34244006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia.
    Danchin MH; Bines JE; Watts E; Cowley D; Pavlic D; Lee KJ; Huque H; Kirkwood C; Nirwati H; At Thobari J; Dewi Satria C; Soenarto Y; Oktaria V
    Vaccine; 2020 Apr; 38(16):3235-3242. PubMed ID: 32160948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.
    Bines JE; At Thobari J; Satria CD; Handley A; Watts E; Cowley D; Nirwati H; Ackland J; Standish J; Justice F; Byars G; Lee KJ; Barnes GL; Bachtiar NS; Viska Icanervilia A; Boniface K; Bogdanovic-Sakran N; Pavlic D; Bishop RF; Kirkwood CD; Buttery JP; Soenarto Y
    N Engl J Med; 2018 Feb; 378(8):719-730. PubMed ID: 29466164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status.
    Boniface K; Byars SG; Cowley D; Kirkwood CD; Bines JE
    J Infect Dis; 2020 Mar; 221(7):1070-1078. PubMed ID: 31763671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia.
    Cowley D; Nirwati H; Donato CM; Bogdanovic-Sakran N; Boniface K; Kirkwood CD; Bines JE
    Vaccine; 2018 Sep; 36(39):5872-5878. PubMed ID: 30145099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.
    Kumru OS; Saleh-Birdjandi S; Antunez LR; Sayeed E; Robinson D; van den Worm S; Diemer GS; Perez W; Caposio P; Früh K; Joshi SB; Volkin DB
    Vaccine; 2019 Oct; 37(44):6696-6706. PubMed ID: 31548012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation Development and Improved Stability of a Combination Measles and Rubella Live-Viral Vaccine Dried for Use in the Nanopatch
    Wan Y; Gupta V; Bird C; Pullagurla SR; Fahey P; Forster A; Volkin DB; Joshi SB
    Hum Vaccin Immunother; 2021 Aug; 17(8):2501-2516. PubMed ID: 33957843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of heat stable lyophilized rotavirus vaccine formulations.
    Madan M; Sikriwal D; Sharma G; Shukla N; Mandyal AK; Kale S; Gill D
    Hum Vaccin Immunother; 2018; 14(9):2132-2141. PubMed ID: 29953317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.